PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke

Stroke

Volumn 29, Issue 1, 1998, Pages 4-11

  Del Zoppo, Gregory J ^a   Higashida, Randall T ^b   Furlan, Anthony J ^e   Pessin, Michael S ^c   Rowley, Howard A ^b   Gent, Michael ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e Scripps Research Institute ^*

Author keywords

Acute; Angiography; Hemorrhage; Pro urokinase; Recanalization; Stroke

Indexed keywords

HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR; SARUPLASE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPARINIZATION; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; TREATMENT OUTCOME;

EID: 0031984356     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.29.1.4     Document Type: Article

References (39)

1. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
2. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42: 976-982.
3. Yamaguchi T, Hayakawa T, Kikuchi H. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993;3:269-272.
4. The National Institute of Neurological Disorders, and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
5. Hacke W, Zeumer H, Ferbert A, Brückmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19:1216-1222.
6. Zeumer H, Freitag H-J, Zanella F, Thie A, Arnig C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase vs recombinant tissue plasminogen activator (rt-PA). Neuroradiology. 1993;35:159-162.
7. del Zoppo GJ, Ferbert A, Otis S, Brückmann H, Hacke W, Zyroff J, Harker LA, Zeumer H. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke. 1988;19:307-313.
8. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;19: 802-812.
9. del Zoppo GJ, Pessin MS, Mori E, Hacke W. Thrombolytic intervention in acute thrombotic and embolic stroke. Semin Neurol. 1991;11:368-384.
10. Wijngaards G, Rijken DC, van Wezel AL, Groeneveld E, van der Velden CA. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res. 1986;42:749-760.
11. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem. 1985;260:12382-12389.
12. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood. 1986;67: 1215-1223.
13. Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res. 1986;44: 217-228.
14. Goldstein LB, Bertels C, Davis JN. Interrater reliability of NIH Stroke Scale. Arch Neurol. 1989;46:660-662.
15. TIMI Study Group. Special report: the Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985;312:932-936.
16. Mahoney F, Barthel D. Functional evaluation: the Barthel index. Md Med J. 1965;14:61-65.
17. Rankin J. Cerebral vascular accidents in patients over the age of 60, II: prognosis. Scott Med J. 1957;2:200-215.
18. Pessin MS. Hemorrhagic transformation in the natural history of acute embolic stroke. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic Therapy in Acute Ischemic Stroke. Heidelberg, Germany: Springer-Verlag; 1991:67-74.
19. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G. Mahagne M-H, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
20. del Zoppo GJ, Higashida RT, Furlan AJ. The case for a phase III trial of cerebral intraarterial fibrinolysis. AJNR Am J Neuroradiol. 1994;15: 1217-1222.
21. Pannell R, Gurewich V. The activation of plasminogen by single chain urokinase or by two-chain urokinase: a demonstration that single chain urokinase has a low catalytic activity (pro-urokinase). Blood. 1987;69: 22-26.
22. Collen D, DeCock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase, II: turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost. 1984;51:24-26.
23. Lijnen HR, VanHoef B, DeCock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood. 1989;73: 1864-1872.
24. Gurewich V, Pannell R, Broeze RJ, Mao J. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin resistant mutant forms produced by site-specific mutagenesis of lysine(158). J Clin Invest. 1988;82:1956-1962.
25. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry. 1991; 30:7630-7638.
26. Burke SE, Lubbers NL, Nelson RA, Henkin J. Recombinant prourokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model. Thromb Haemost. 1993; 69:375-380.
27. Abbott Laboratories Scientific Report PPRd/89/541. Evaluation of recombinant pro-urokinase (ABBOTT-74187) in the canine femoral artery clot lysis model (December 27, 1989). IND 3472 Serial No. 000. 1989.
28. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination or both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
29. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Bessorn G, Leys D, Amarenio P, Bogart M, for the MAST Group. Termination of trial of streptokinase in severe acute ischemic stroke. Lancet. 1995;345:578-579. Letter.
30. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EC, Tuck RR. Trials of streptokinase in severe acute ischaemic stroke. Lancet. 1995;345:578-579.
31. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
32. Libman RB, Sacco RL, Mohr JP. Improvement following stroke. Stroke. 1996;27:148-149.
33. Furlan AJ. Natural history of atherothromboembolic occlusion of cerebral arteries: carotid versus vertebrobasilar territories. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic Therapy in Acute Ischemic Stroke. New York, NY: Springer-Verlag; 1991:71-76.
34. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci. 1989;91:311-321.
35. Feinstein AR. Clinimetrics. New Haven, Conn: Yale University Press; 1987.
36. Hantson L, De Weerdt W, De Keyser J, Diener HC, Franke C, Palm R, Van Orshoven M, Schoonderwalt H, De Klippel N, Herroelen L, Feys H. The European Stroke Scale. Stroke. 1994;25:2215-2219.
37. Mani RL, Eisenberg RL, McDonald EJ, Pollock JA, Mani JR. Complications of catheter cerebral arteriography: analysis of 5,000 procedures, I: criteria and incidence. AJR Am J Roentgenol. 1978;131:861-865.
38. Mani RL, Eisenberg RL. Complications of catheter cerebral arteriography: analysis of 5,000 procedures, II: relation of complication rates to clinical and arteriographic diagnosis. AJR Am J Roentgenol. 1978;131:867-869.
39. Mani RL, Eisenberg RL, McDonald EJ, Pollock JA, Mani JR. Complications of catheter cerebral arteriography: analysis of 5,000 procedures, III: assessment of arteries injected, contrast medium used, duration of procedure, and age of patient. AJR Am J Roentgenol. 1978;131:871-874.